Assessment and treatment of depression, anxiety, or related disorders
AssigneesDuke University, Emoory University, University of California Davis
InventorsRima F. Kaddurah-Daouk, Augustus John Rush, JR., Boadie W. Dunlop, Oliver Fiehn, Christopher R. Brydges, W. Edward Craighead, Helen Mayberg
Life of this patent
Estimating the term…
Abstract
Described herein are methods of identifying, characterizing, and treating depression and anxiety in a subject by modulating indoles associated with tryptophan metabolism in the subject and subject's gut microbiome.
Claims54
A method for treating a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or a combination thereof by modulating the gut microbiome composition or enzymatic activity of the subject, the method comprising:
- (a) increasing the level of indole-3-propionic acid producing bacteria;
- (b) decreasing the level of indoxyl sulfate producing bacteria;
- (c) inhibiting bacterial enzymes that produce indoxyl sulfate;
- (d) activating bacterial enzymes that produce indole-3-propionic acid;
- or
- a combination of any of (a)-(d).
A method for treating a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combination thereof by characterizing the gut microbiome metabolic profile of the subject, the method comprising:
- (a) obtaining one or more biological samples from the subject;
- (b) measuring a baseline concentration of one or more tryptophan gut metabolites selected from indoxyl sulfate, indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof;
- (c) determining baseline ratios of indoxyl sulfate concentration to the concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, and indole-3-lactate, wherein increased baseline ratios of indoxyl sulfate indicate that the subject is suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety or combination thereof;
- and
- (d) administering a therapy to the subject when increased ratios of indoxyl sulfate are determined.
A method for stratifying one or more subjects suffering from a neuropsychiatric disease, disorder, or condition, including depression, major depressive disorder, anxiety, or combinations thereof into subgroups based on individual gut microbiome composition, enzymatic activity, concentrations and ratios of metabolites produced by gut bacteria, or combinations thereof, the method comprising:
- (a) obtaining one or more biological samples from the subjects;
- (b) measuring a baseline concentration of one or more tryptophan gut metabolites selected from indoxyl sulfate, indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof;
- (c) determining a baseline ratio of indoxyl sulfate concentration to concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof;
- (d) stratifying the subjects into subgroups based on the determined baseline ratios of indoxyl sulfate concentration to concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof;
- and
- (e) assessing disease severity of subjects in each stratified subgroup.
Use of a therapeutic agent to trap and sequester indoxyl sulfate for the treatment of a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof.
Use of an indole-3-propionic acid producing probiotic gut bacterial strain for the treatment of a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof.
Use of a therapeutic agent to inhibit enzymatic activity of sulfotransferase liver enzymes that produce indoxyl sulfate for the treatment of a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof.
Use of a therapeutic agent to inhibit aryl hydrocarbon receptor activity of intestinal immune cells for the treatment of a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof.
A method for treating a subject suffering from, or at risk of suffering from, immune metabolic depression, anxiety, or combinations thereof by characterizing the gut microbiome metabolic profile of the subject, the method comprising:
- (a) obtaining one or more biological samples from the subject;
- (b) measuring a concentration of one or more tryptophan gut metabolites selected from indoxyl sulfate, indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof;
- (c) determining ratios of indoxyl sulfate concentration to the concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof, wherein increased ratios of indoxyl sulfate indicate that the subject is suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof;
- (d) measuring aryl hydrocarbon receptor activity of intestinal immune cells;
- and
- (e) administering a therapy to the subject when increased ratios of indoxyl sulfate are determined.
Dependencies are inferred from the claim text.